Quoin Pharmaceuticals (Nasdaq: QNRX) announced that it has submitted an application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orphan Drug Designation (ODD)…
January 27, 2026
Several developments across large-cap pharma and emerging biotech this week are sharpening investor focus on commercial execution, pipeline optionality, and near-term regulatory catalysts — with…
Sanofi (NASDAQ: SNY) makes plans to pursue regulatory approval for amlitelimab, its late-stage treatment for atopic dermatitis, despite mixed results from Phase 3 clinical trials….
Alzheimer’s disease remains one of the most challenging areas in medicine, but a new wave of therapies is moving beyond traditional amyloid-only approaches. These next-generation…
The U.S. Food and Drug Administration has issued new draft guidance aimed at speeding the development and approval of treatments for multiple myeloma, a highly…
Laser Photonics (NASDAQ: LASE) announced a $1.3 million order from a new international pharmaceutical customer for its high-throughput tablet laser drilling system, marking another meaningful…
Avadel Pharmaceuticals (NASDAQ: AVDL) is drawing renewed investor attention as its share price continues to reflect optimism around the company’s clinical progress and strategic outlook….
AbbVie (NYSE: ABBV) announced it has entered into a new Most-Favored-Nation (MFN) drug pricing agreement with the U.S. government under recent federal drug pricing reforms….
January 12, 2026
AbbVie Inks $5.6B Bispecific Deal with RemeGen
AbbVie Inc. (NYSE: ABBV) is making a massive bet on the next generation of cancer treatment. The pharmaceutical giant recently signed an exclusive licensing agreement…
January 06, 2026
AI-Driven ERP Agents: New Competitive Edge for Pharma
Pharmaceutical companies are increasingly exploring artificial intelligence (AI) agents integrated with Enterprise Resource Planning (ERP) systems to automate routine business processes — from supplier communications…
December 29, 2025
Sellas Life Sciences Updates Pivotal Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
Sellas Life Sciences Group, Inc. (NASDAQ: SLS) provided a progress update on its ongoing pivotal Phase 3 REGAL clinical trial evaluating galinpepimut-S (GPS) in patients…
December 29, 2025
Johnson & Johnson Completes Acquisition of Halda Therapeutics, Expanding Next-Generation Oncology Platform
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Halda Therapeutics, bringing Halda’s novel therapeutic platform and clinical-stage oncology programs into Johnson & Johnson’s…